M.I.F.: effect on levodopa dyskinesias in man.
D000978:Antiparkinson Agents / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D003653:Decarboxylation; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009074:Melanocyte-Stimulating Hormones / Q000378:metabolism*; D008745:Methylation; D009069:Movement Disorders / Q000139:chemically induced*; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D004295:Dihydroxyphenylalanine; D009074:Melanocyte-Stimulating Hormones; D002262:Carboxy-Lyases; D002230:Carbidopa